FDA approves Ibrance for postmenopausal women with advanced breast cancer
The U.S. Food and Drug Administration today granted accelerated approval to Ibrance (palbociclib) to treat advanced (metastatic) breast cancer.
-
Subscribe
Subscribe via the RSS feed